World's Best Scientists 2026 revealed!
Award Badge
Rising Stars
2025

D-Index & Metrics

Rising Stars

D-Index
104
Citations
82413
World Ranking
3
National Ranking
1

Medicine

D-Index
108
Citations
94675
World Ranking
5855
National Ranking
3142

Research.com Recognitions

  • 2025 - Research.com Rising Stars Award

Overview

Matthew D. Hellmann is affiliated with the Memorial Sloan Kettering Cancer Center in the United States. Their research primarily focuses on oncology, with significant contributions to cancer immunotherapy, lung cancer treatments, and cancer genomics.

Their work spans several subfields including oncology, pulmonary and respiratory medicine, immunology, cancer research, and molecular biology. The main topics covered in their publications include:

  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Cancer Genomics and Diagnostics
  • CAR-T cell therapy research
  • Lung Cancer Research Studies
  • Immunotherapy and Immune Responses
  • Lung Cancer Diagnosis and Treatment

Matthew D. Hellmann has contributed research to prominent publication venues such as:

  • Cancer
  • Journal of Clinical Oncology
  • Cancer Research
  • Annals of Oncology
  • Journal of Thoracic Oncology

The following are some of the recent papers associated with their research activity, showcasing publication year and venue:

  • "Acquired Resistance to Immune Checkpoint Inhibitors," 2020, Cancer Cell
  • "Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition," 2021, Cell
  • "A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer," 2020, Cell
  • "Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers," 2021, Nature
  • "Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction," 2020, Cell

Frequent co-authors collaborating with Matthew D. Hellmann include:

  • Hira Rizvi
  • Charles M. Rudin
  • Joel W. Neal
  • Keunchil Park
  • Andrew J. Plodkowski

Matthew D. Hellmann's work is characterized by a substantial volume of publications in the field of medicine, with 352 publications attributed to this domain. Their focused research on cancer immunotherapy and lung cancer reflects in the breadth and depth of studies contributing to the understanding and advancement of treatment strategies in these areas.

Best Publications

  • Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

    Naiyer A. Rizvi;Naiyer A. Rizvi;Matthew D. Hellmann;Matthew D. Hellmann;Alexandra Snyder;Alexandra Snyder;Pia Kvistborg

  • Pembrolizumab for the treatment of non-small cell lung cancer

    Edward B. Garon;Naiyer A. Rizvi;Rina Hui;Natasha Leighl

  • Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

    Bertrand Routy;Bertrand Routy;Bertrand Routy;Lisa Derosa;Lisa Derosa;Lisa Derosa;Connie P. M. Duong;Connie P. M. Duong

  • Tumor mutational load predicts survival after immunotherapy across multiple cancer types.

    Robert M Samstein;Chung-Han Lee;Chung-Han Lee;Alexander N Shoushtari;Alexander N Shoushtari;Matthew D Hellmann;Matthew D Hellmann

  • Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

    Michael A Postow;Robert Sidlow;Matthew D Hellmann

  • Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

    Nicholas McGranahan;Nicholas McGranahan;Andrew J. S. Furness;Rachel Rosenthal;Sofie Ramskov

  • Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

    Ahmet Zehir;Ryma Benayed;Ronak H Shah;Aijazuddin Syed

  • Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

    Matthew D. Hellmann;Tudor-Eliade Ciuleanu;Adam Pluzanski;Jong Seok Lee

  • Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

    Matthew D Hellmann;Luis Paz-Ares;Reyes Bernabe Caro;Bogdan Zurawski

  • Neoadjuvant PD-1 Blockade in Resectable Lung Cancer

    Patrick M. Forde;Jamie E. Chaft;Kellie N. Smith;Valsamo Anagnostou

  • OncoKB: A Precision Oncology Knowledge Base.

    Debyani Chakravarty;Jianjiong Gao;Sarah Phillips;Ritika Kundra

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.

    Hira Rizvi;Francisco Sanchez-Vega;Konnor La;Walid Chatila

  • Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

    Scott N. Gettinger;Leora Horn;Leena Gandhi;David R. Spigel

  • Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

    Diana Miao;Diana Miao;Claire A. Margolis;Claire A. Margolis;Wenhua Gao;Martin H. Voss;Martin H. Voss

  • Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

    Matthew D. Hellmann;Tavi Nathanson;Hira Rizvi;Benjamin C. Creelan

  • Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

    Jarushka Naidoo;Xuan Wang;Xuan Wang;Xuan Wang;Kaitlin M. Woo;Kaitlin M. Woo;Tunc Iyriboz;Tunc Iyriboz

  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

    Matthew D. Hellmann;Naiyer A. Rizvi;Jonathan W. Goldman;Scott N. Gettinger

  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

    Leora Horn;David R. Spigel;Everett E. Vokes;Esther Holgado

  • Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

    Kathryn C. Arbour;Laura Mezquita;Niamh Long;Hira Rizvi

Frequent Co-Authors

Mark G. Kris
Mark G. Kris Memorial Sloan Kettering Cancer Center
Charles M. Rudin
Charles M. Rudin Memorial Sloan Kettering Cancer Center
Julie R. Brahmer
Julie R. Brahmer Johns Hopkins University
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Gregory J. Riely
Gregory J. Riely Memorial Sloan Kettering Cancer Center
Naiyer A. Rizvi
Naiyer A. Rizvi Columbia University Medical Center
Taha Merghoub
Taha Merghoub Cornell University
Mark M. Awad
Mark M. Awad Harvard University
Marc Ladanyi
Marc Ladanyi Memorial Sloan Kettering Cancer Center
Suresh S. Ramalingam
Suresh S. Ramalingam Emory University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you are exploring alternative routes or complementary fields to studying medicine in the USA, several online options can expand your healthcare career opportunities. One popular path is the accelerated healthcare administration degree online, offering a fast-track for students wanting to move into management or leadership roles in healthcare organizations.

For nurses aiming to advance their practice, there are asn to nurse practitioner programs that help registered nurses with an associate’s degree transition directly into advanced practice roles by earning a master’s degree online.

Nutrition is another growing area within healthcare. The best online nutrition programs provide flexible options for students interested in dietetics, wellness coaching, or public health nutrition careers.

If your interest lies in healthcare management, it’s important to consider accreditation. Learn more about which online healthcare administration programs have cahme accreditation?, ensuring your degree meets high industry standards and boosts your employability.

Best Scientists Citing Matthew D. Hellmann

Trending Scientists

Recently Published Articles